"The voice for cancer physicians and their patients in Massachusetts." |
In addition to all the other membership benefits, MSCO is investing in the future of oncology by supporting the professional development and research of young clinicians and Fellows.
The Massachusetts Society of Clinical Oncology (MSCO) is pleased to announce that as part of our efforts to support the growth and future of the oncology profession, we will be providing a grant for oncology professionals from Massachusetts to travel to the ASCO Annual Meeting.
Among the recipients of the MSCO Travel Award will be one fellow of an ACGME-accredited training program and one young clinician (with less than five years of practice).
The application deadline is April 15.
Download application and submission requirementsThe Massachusetts Society of Clinical Oncologists (MSCO) is proud to annually fund one Young Investigator Award (YIA) for a qualified Massachusetts applicant through Conquer Cancer, the ASCO Foundation. We encourage all eligible Massachusetts Fellows and Trainees to apply. The YIA is a one-year, $57,500 grant that provides research funding to promising physicians to support their transition from final years of subspecialty training to faculty appointment and to encourage and promote quality research in clinical oncology. For questions about eligibility, please contact Conquer Cancer at grants@conquer.org.
A Phase 1 study of adding navitoclax to the combination of venetoclax and decitabine for advanced myeloid malignancies.
Evan Chen, MD a third year Hematology/Oncology fellow at the Dana-Farber Cancer Institute (DFCI). He is a clinical investigator-in-training who seeks to improve precision medicine for myeloid malignancies through the clinical trial development of novel therapeutics and the retrospective study of their real-world outcomes. He is currently helping to lead a phase I study of navitoclax added to the combination of venetoclax and hypomethylating agents for advanced myeloid malignancies. He recently joined the Division of Leukemia at DFCI.
A Phase 2 trial of palbociclib in combination with axitinib and avelumab in metastatic clear cell renal cell carcinoma.
Praful Ravi, MBBChir, MRCP, a Medical Oncologist at the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, is the recipient of the inaugural YIA Award supported by MSCO.
Quality and Innovation GrantThe purpose of the MSCO Quality & Innovation Grant is to improve the care of patients in the state of Massachusetts living with a diagnosis of cancer. Funding will be provided for an individual or a group seeking to improve the deliver of cancer care, the quality of cancer care, treatment of cancer, or comfort of patients suffering from cancer. Past Grant Recipients2019 Adapting the Electronic Patient Reported Outcomes (EPRO) Intervention to Improve Cancer Care Delivery and Clinical Outcomes of Limited-English Proficiency (LEP) Individuals Diagnosed with Advanced Gastrointestinal or Breast Cancer Nadine McCleary, MD, MPH 2017 Oral Chemotherapy Management with Electronic Patient Reporting--A Community and Academic Hybrid Model Jessica Zerillo, MD, PhD and Meghan Shea, MD
Chris Wong Quiles, MD, MPH, CPPS 2015 Feasibility, acceptability and effectiveness of the MBSR for smoking cessation in cancer patients Marjory Charlot, MD, MPH, MSc |